Venn Life Sciences Holdings PLC (LON:VENN) Rating
Venn Life Sciences Holdings PLC (LON:VENN) stock had its Speculative Buy Rating reconfirmed by equity analysts at Beaufort Securities in analysts note issued on Thursday morning.
About 73,129 shares traded hands or 16.59% up from the average. Venn Life Sciences Holdings PLC (LON:VENN) has risen 27.85% since February 29, 2016 and is uptrending. It has outperformed by 16.59% the S&P500.
Venn Life Sciences Holdings plc is a clinical research organization , which is engaged in providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology and medical device organizations. The company has a market cap of 15.18 million GBP. The Firm has the innovation segment, which is focused on developing and commercializing skin technologies. It currently has negative earnings. It provides drug development services through its subsidiary, Kinesis Pharma B.V.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.